Macular Grid Photocoagulation for Macular Edema in Central Retinal Vein Occlusion

Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion

“…Loss of visual function due to CRVO or BRVO is mainly caused by macular edema (ME). Treatment strategies for ME comprise laser treatment (BRVO), intravitreal steroids, surgical procedures [1][2][3][4][5] and, most recently, off-label intravitreal injection of anti-VEGF agents. There is increasing evidence that intravitreal injection of bevacizumab can lead to significant reduction of ME [6][7][8].…”

Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion

“…Loss of visual function due to CRVO or BRVO is mainly caused by macular edema (ME). Treatment strategies for ME comprise laser treatment (BRVO), intravitreal steroids, surgical procedures [1][2][3][4][5] and, most recently, off-label intravitreal injection of anti-VEGF agents. There is increasing evidence that intravitreal injection of bevacizumab can lead to significant reduction of ME [6][7][8].…”

Periocular Gene Transfer of sFlt-1 Suppresses Ocular Neovascularization and Vascular Endothelial Growth Factor-Induced Breakdown of the Blood-Retinal Barrier

“…Therefore, it is likely that VEGF plays an important role in the development of macular edema as well as retinal neovascularization in patients with ischemic retinopathies. Macular edema is an extremely prevalent problem for which current treatments are inadequate (Branch Vein Occlusion Study Group, 1984;Diabetic Retinopathy Study Research Group, 1985;Central Vein Occlusion Study Group, 1995). Our findings suggest that periocular gene transfer of sFlt-1 may provide a new approach for treatment of macular edema in ischemic retinopathies.…”

Glaucoma and visual outcome in central retinal vein occlusion

“…In addition, it should be noted that the difference in the final visual acuity resulted mainly from the large proportion of eyes with glaucoma that deteriorated to the finger counting to no light perception category. It is hard to believe that macular laser treatment could have been effective in preventing such a substantial deterioration (Klein & Finkelstein 1989).…”

Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion

“…Loss of visual function due to CRVO or BRVO is mainly caused by macular edema (ME). Treatment strategies for ME comprise laser treatment (BRVO), intravitreal steroids, surgical procedures [1][2][3][4][5] and, most recently, off-label intravitreal injection of anti-VEGF agents. There is increasing evidence that intravitreal injection of bevacizumab can lead to significant reduction of ME [6][7][8].…”

Periocular Gene Transfer of sFlt-1 Suppresses Ocular Neovascularization and Vascular Endothelial Growth Factor-Induced Breakdown of the Blood-Retinal Barrier

“…Therefore, it is likely that VEGF plays an important role in the development of macular edema as well as retinal neovascularization in patients with ischemic retinopathies. Macular edema is an extremely prevalent problem for which current treatments are inadequate (Branch Vein Occlusion Study Group, 1984;Diabetic Retinopathy Study Research Group, 1985;Central Vein Occlusion Study Group, 1995). Our findings suggest that periocular gene transfer of sFlt-1 may provide a new approach for treatment of macular edema in ischemic retinopathies.…”

Glaucoma and visual outcome in central retinal vein occlusion

“…In addition, it should be noted that the difference in the final visual acuity resulted mainly from the large proportion of eyes with glaucoma that deteriorated to the finger counting to no light perception category. It is hard to believe that macular laser treatment could have been effective in preventing such a substantial deterioration (Klein & Finkelstein 1989).…”

Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion

“…Loss of visual function due to CRVO or BRVO is mainly caused by macular edema (ME). Treatment strategies for ME comprise laser treatment (BRVO), intravitreal steroids, surgical procedures [1][2][3][4][5] and, most recently, off-label intravitreal injection of anti-VEGF agents. There is increasing evidence that intravitreal injection of bevacizumab can lead to significant reduction of ME [6][7][8].…”

Periocular Gene Transfer of sFlt-1 Suppresses Ocular Neovascularization and Vascular Endothelial Growth Factor-Induced Breakdown of the Blood-Retinal Barrier

“…Therefore, it is likely that VEGF plays an important role in the development of macular edema as well as retinal neovascularization in patients with ischemic retinopathies. Macular edema is an extremely prevalent problem for which current treatments are inadequate (Branch Vein Occlusion Study Group, 1984;Diabetic Retinopathy Study Research Group, 1985;Central Vein Occlusion Study Group, 1995). Our findings suggest that periocular gene transfer of sFlt-1 may provide a new approach for treatment of macular edema in ischemic retinopathies.…”

Glaucoma and visual outcome in central retinal vein occlusion

“…In addition, it should be noted that the difference in the final visual acuity resulted mainly from the large proportion of eyes with glaucoma that deteriorated to the finger counting to no light perception category. It is hard to believe that macular laser treatment could have been effective in preventing such a substantial deterioration (Klein & Finkelstein 1989).…”